

Open Peer Review on Qeios

Mimotope-P10s-PADRE Peptide Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>Mimotope-P10s-PADRE Peptide Vaccine</u>. NCI Thesaurus. Code C123381.

A peptide-based vaccine containing a carbohydrate mimetic peptide (CMP) P10s fused to the pan HLA DR-binding epitope (PADRE) peptide, with immunomoadjuvant activity and potential antineoplastic activity. Upon injection of the mimotope-P10s-PADRE peptide vaccine, the P10s peptide, which mimics gangliosides and other tumor-associated carbohydrate antigens (TACA), both stimulates a cytotoxic T-lymphocyte (CTL) response towards cells expressing TACAs and induces the production of antibodies that are reactive with a broad set of TACAs. Additionally, the anti-TACA antibodies may interfere with cellular pathways involved in tumor cell survival and may induce antibody-dependent cellular cytotoxicity (ADCC) toward cells expressing TACAs. PADRE is a helper T-cell epitope that is able to increase the magnitude and duration of the CTL response.

Qeios ID: 41T6Y4 · https://doi.org/10.32388/41T6Y4